Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15538697 | 0.90 | MET (0.73) | METGAA | |
| SCHEMBL15539601 | 0.86 | MET (0.60) | METGAA | |
| SCHEMBL15539645 | 0.85 | MET (0.60) | METGAA | |
| SCHEMBL15538650 | 0.83 | MET (0.56) | METGAA | |
| SCHEMBL15538469 | 0.81 | MET (0.57) | METGAA | |
| SCHEMBL15539468 | 0.77 | MET (0.56) | METGAA | |
| SCHEMBL23621423 | 0.76 | MET (0.75) | METGAA | |
| SCHEMBL15537707 | 0.74 | GAA (0.52) | METGAA | |
| SCHEMBL12501011 | 0.73 | GAA (1.00) | METGAA | |
| SCHEMBL15538094 | 0.73 | GAA (0.67) | METGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875006-B1 | ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2018-12-26 | — | — | EP | disclosed |
| US-9428465-B2 | Acid ceramidase inhibitors and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2016-08-30 | — | — | US | disclosed |
| EP-2875006-A1 | ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | Fondazione Istituto Italiano Di Tecnologia (IT) | 2015-05-27 | — | — | EP | disclosed |
| US-20150111892-A1 | ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-23 | — | — | US | disclosed |
| WO-2013178576-A1 | ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2013-12-05 | — | — | WO | disclosed |
| US-20080319064-A1 | DEUTERIUM-ENRICHED OSELTAMIVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111892-A1 | ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | ASAH1, ASAH2, ACER2 | MET 4321/4885GAA 16/4885 |
| US-20080319064-A1 | DEUTERIUM-ENRICHED OSELTAMIVIR | HDHD5, SLC28A1, SAMHD1 | MET 2033/4885GAA 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.